Group 1 - The stock of Haohai Biological Technology (688366) has a comprehensive score of 47.92, indicating a weak performance [1] - The main cost analysis shows that the current main cost is 50.41 yuan, with a 5-day main cost of 50.79 yuan and a 20-day main cost of 51.67 yuan [1] - There have been no instances of the stock hitting the upper or lower limits in the past year [1] Group 2 - On July 4, 2025, the net outflow of main funds was 387.01 million yuan, accounting for 12% of the total transaction amount [2] - The short-term pressure level is at 51.24 yuan, while the short-term support level is at 50.15 yuan [2] - The medical device sector showed a slight decline, with the medical device concept down by 0.40% and medical beauty down by 0.65% [2]

| 招商通知 | | --- | | 第三届全球手术机器人大会 | | 第二届全球医疗科技大会 | 2025年7月1日 ， 专 注胶囊内窥镜技术创新的医疗科技公司 CapsoVision, Inc.（纳斯达克代码：CV） ，宣布其 首次公开募股 （IPO） 定价为每股 5.00 美元，共发行 550 万股普通股，预计募资 约2750万美元（约合人民币2亿） 。 股票于 7 月 2 日在纳斯达克 资本市场开始交易。这次发行不仅是融资事件，更意味着这家专注胃肠道诊断创新的公司，正试图在全球医疗市场中占据更重要的位 置。 CapsoVision 的首席执行官 Dean Burns 在公司发布会上表示："从一开始，我们的目标就是让胶囊内窥镜不仅能看见，更能看全。今 天的 IPO，是让我们更接近这个愿景的重要一步。" # 市 场与竞 争环 境 全球胶囊内窥镜市场预计到 2030 年将达到 12 亿美元。推动这一市场发展的核心动力是人口老龄化、消化道疾病患病率上升，以及人 们对非侵入性检查方式的偏好。特别是在结直肠癌筛查领域，随着人们预防意识增强，非侵入式检测的需求愈加迫切。 然而，CapsoVision 面对的竞争也异 ...

计算机行业 2025 年 7 月 4 日 卢芷心 S0340524100001 电话：0769-22119297 邮箱： luzhixin@dgzq.com.cn 罗炜斌 S0340521020001 电话：0769-22110619 邮箱： luoweibin@dgzq.com.cn 陈伟光 S0340520060001 电话：0769-22119430 邮箱： chenweiguang@dgzq.com.cn 资料来源：iFinD，东莞证券研究所 超配（维持） 计算机行业双周报（2025/6/20-2025/7/3） 行 业 国内科技巨头争相抢滩 AI 医疗，有望加快 AI 垂类应用场景落地 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 SAC 执业证书编号： 计 算 机 行 业 指 数 涨 跌 幅 及 估 值 ： 申 万 计 算 机 板 块 近 2 周 （2025/6/20-2025/7/3）累计上涨4.48%，跑赢沪深300指数1.23个百分 点，在31个申万一级行业中排名第15名；申万 ...

Core Viewpoint - The stock of Nanwei Medical (688029) shows strong performance indicators with a comprehensive score of 63.83, indicating a robust trend direction and potential for short-term and mid-term gains [1][2][3] Group 1: Stock Performance - The stock price has broken through short-term resistance levels, suggesting potential for short-term strength; similarly, breaking through mid-term resistance levels indicates potential for mid-term strength [2][3] - The stock has not experienced any limit-up or limit-down events in the past year [1] Group 2: Financial Data - As of July 4, 2025, the company reported earnings per share of 0.86 yuan and an operating profit of 1.98 billion yuan [2][3] - The net profit stands at approximately 167.16 million yuan, with a sales gross margin of 65.689% [2][3] Group 3: Capital Flow - On July 4, 2025, the net inflow of main funds was 23.54 million yuan, accounting for 12% of the total transaction volume [2][3] - The data indicates a net inflow of 6.44 million yuan from large orders and a net inflow of 17.10 million yuan from super large orders, while retail investors experienced a net outflow of 703,400 yuan [2][3] Group 4: Market Context - The stock is associated with the medical device sector, which saw a slight increase of 0.18%, while the medical device concept experienced a decrease of 0.40% [2][3]

Core Viewpoint - The company reported a decline in revenue and profit for 2024, but showed signs of recovery in Q1 2025, with a focus on both domestic and international market expansion [1][2][3]. Financial Performance - In 2024, the company achieved revenue of 10.3 billion yuan, a decrease of 9.73%, and a net profit of 1.262 billion yuan, down 36.1% [1]. - Q4 2024 revenue was 3.35 billion yuan, down 15.91%, with a net profit of 591 million yuan, down 35.1% [1]. - In Q1 2025, revenue increased to 2.478 billion yuan, up 5.42%, with a net profit of 370 million yuan, up 1.87% [1]. Business Segments - Domestic sales of medical imaging and radiation therapy equipment generated 8.445 billion yuan, a decline of 14.93%, while the service segment grew by 26.81% to 1.356 billion yuan [2]. - International revenue reached 2.266 billion yuan, an increase of 35.08%, accounting for 22% of total revenue, driven by market penetration in high-end segments [2]. R&D and Innovation - The company invested 2.261 billion yuan in R&D in 2024, representing 21.95% of revenue, and 568 million yuan in Q1 2025, accounting for 22.92% of revenue [3]. - The company has achieved significant advancements in technology across various product lines, establishing a competitive edge in the market [3]. Market Strategy - The company is focusing on a dual strategy of high-end product development and comprehensive market penetration domestically, while enhancing localized operations internationally [3]. - The global service network now covers over 85 countries and regions, supporting the operational needs of more than 34,500 devices [3].

来源：健业家 | | | | 2025年医疗健康IP0统计 | | | | --- | --- | --- | --- | --- | --- | | 企业 | 行业 | 上市状态 | 在北 | 行业 | 上市状态 | | 劲方医药 | 创新药 | 港股域表 | 阿正中医 | 中医 | 港股进表 | | 先通医药 | 创新药 | 港股越表 | 同仁堂医养 | 中医 | 港股进表 | | 迈威生物 | 创新药 | 港股邊表 | 新荷花中药饮片 | 中医 | 港股进表 | | 百利天恒 | 创新药 | 港股速表 | 微医 | 互联网医疗 | 港股进表 | | 宝济药业 | 创新药 | 港股域表 | 微脉 | 互联网医疗 | 港股进表 | | 科望医药 | 创新药 | 港股递表 | 健康160 | 互联网医疗 | 港股进表 | | 景泽生物 | 创新药 | 港股递表 | 轻松健康 | 保险 | 港股进表 | | 旺山旺水生物 | 创新药 | 港股遗表 | 镁信健康 | 保障 | 港股通表 | | 真实生物 | 创新药 | 港股越表 | 大医集团 | 医疗器械 | 港股进表 | | 亦诺微 | 创新药 | 港股递表 ...

公立医疗机构开展血透、腹透等医疗服务均按整合后项目收费，不得选用其他医疗服务价格项目进行收 费。比如，开展血液透析同时联合血液灌流服务，可按照"血液透析灌流费"收费，不得拆分项目分别收 费。 根据相关通知，原"人工肝治疗"项目废止，实际进行的血浆置换、血浆吸附、连续性肾脏替代治疗等操 作可按相应项目叠加收费；原实施血液透析、血液滤过、血液灌流等项目的住院患者床旁治疗加收政策 同时废止。 近日，广东省医保局连续发布通知，公布了优化整合后的泌尿系统透析类、超声和中医类等医疗服务价 格项目和政府指导价（全省最高限价），并要求各地市确保血透患者负担不增加。 其中，泌尿系统透析类医疗服务价格项目和政府指导价自7月15日起实施，超声和中医类等医疗服务价 格项目和政府指导价自7月31日起实施。 不得拆分项目分别收费 广东将原实施的"机采血浆置换术"等32项规范整合为"血液透析费"等21项血透类医疗服务价格项目，将 原实施项目和规范后项目进行映射，并制定了全省最高限价。 相关通知明确，各地市在确保血透患者负担不增加的情况下平移血液透析服务项目价格。"血液透析 费"项目的全省最高限价为每次390元，所定价格涵盖消毒、穿刺、安装 ...

Core Insights - Global smartwatch shipments declined by 2% year-on-year in Q1 2025, marking the fifth consecutive quarter of decline, primarily due to a slowdown in the Indian market and a decrease in Apple smartwatch shipments [1][3] - In contrast, the Chinese market saw a significant increase of 37% in shipments year-on-year, achieving the highest market share since Q4 2020, driven by strong performance from domestic brands [1][3] Company Performance - Apple remains the market leader despite a six-quarter decline in shipments, benefiting from an expanding iOS user base [3] - Huawei and Xiaomi experienced significant growth in shipments, attributed to strong domestic performance, a diverse product portfolio, and competitive pricing strategies targeting the mid-to-high-end market [3] - Samsung's previous generation products underperformed in major global markets, resulting in an 18% year-on-year decline in quarterly shipments [3] Market Trends - There is a notable shift in consumer preferences towards higher price segments, with shipments in the $100 to $200 range increasing by 21%, indicating a rising demand for products with enhanced health and fitness features [5] - Conversely, entry-level products (under $100) saw a 17% year-on-year decline, suggesting consumers are willing to pay a premium for accuracy, stability, and ecosystem compatibility [5] - The children's smartwatch segment continues to grow significantly, with brands like Xiaotiancai leading due to high cost-performance ratios and rich functionalities [5] Future Outlook - The global smartwatch market is expected to recover at a moderate pace of approximately 3% in 2025, driven by advancements in product capabilities, including the integration of AI features and next-generation health sensors [5] - Changing consumer behavior is shifting focus from novelty to product functionality, long-term value, and ecosystem compatibility, leading to a preference for reliable devices that support health, productivity, and lifestyle goals [5]

截至2025年7月4日 13:17，恒生医疗保健指数(HSHCI)强势上涨1.19%，成分股华昊中天医药-B(02563)上涨16.34%，康方生物(09926)上涨8.67%，云顶新耀 (01952)上涨6.95%，科伦博泰生物-B(06990)，药明合联(02268)等个股跟涨。恒生医疗ETF(513060)上涨0.86%，最新价报0.59元。拉长时间看，截至2025年7 月3日，恒生医疗ETF近1周累计上涨3.57%。 流动性方面，恒生医疗ETF盘中换手18.66%，成交15.16亿元，市场交投活跃。拉长时间看，截至7月3日，恒生医疗ETF近1月日均成交22.00亿元，居可比基 金第一。 消息面上，7月3日早间，康方生物宣布，自主研发的首个双抗ADC药物AK146D1治疗晚期实体瘤的Ia期临床研究完成首例受试者入组。该药已获美国 FDA、澳大利亚TGA和中国国家药监局批准开展临床试验。 华泰证券认为，AI有望重塑新药研发的生产模式、医疗服务的提供方式，其在医疗领域的应用将越来越广泛，涵盖病理研究、药物研发等几乎所有医疗环 节。"AI + 医疗" 此前被市场低估，随着相关技术成本降低和应用推进，2025 ...

证券研究报告 稳健医疗 (300888 CH) 品牌势能向上，核心品类表现亮眼 2025 年 7 月 04日│中国内地 消费轻工 作为"消费+医疗"双轮驱动的大健康企业，公司"winner 稳健医疗"和 "Purcotton 全棉时代"两大品牌影响力不断提升。2025 年以来，1）消费 品坚持产品领先战略，营销&渠道端打法优化，经营渐入佳境，Q2 终端销 售虽因舆情事件影响短期有波动，但随着营销回归正常轨道叠加新品投放， 板块收入有望保持增长势能；2）医疗板块受益于"内生+外延"双轮驱动， 板块收入有望筑底回升。立足当前，我们看好公司双轮成长驱动力，2025 年轻装上阵，经营势能突出，维持"买入"评级。 近况跟踪：618 大促顺利收官，核心单品表现亮眼 1Q25 公司消费品板块实现营收 13.4 亿元/同比+28.8%，Q2 由于"315"行 业舆情事件扰动，我们预计 Q2 板块收入同比增速环比 Q1 有所放缓，但核 心品类仍表现优异。今年 618 期间，公司通过产品创新升级、新品迭代、精 准营销等方式，重点品类及渠道发展提升明显，洗脸巾、婴童干湿巾、婴童 抱被等在天猫、京东电商平台销售额在同类目中均排第一； ...